UK initiative to harness big biological data sets and look deeper into how the human body works and malfunctions ...

AI-powered tools like Merck’s Aiddison can accelerate drug identification and optimise design, cutting both costs and time to ...

It’s the ultimate in home convenience; a robot vacuum that will pick up after you, ticking one big household chore off your list. No more having to coax the ones you live with to vacuum when it ...

Get our weekly Home and Garden email for tips, and interior inspiration Robot vacuum cleaners are more advanced and more affordable than ever. Once a novelty gadget, these household helpers are ...

'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

NVIDIA stock has also fallen by 5.7% this year. The other top laggards in the fund are Merck, UnitedHealth Group, Honeywell, Caterpillar, and Microsoft. On the other hand, the top gainers in the ...

We’ve been testing robot vacuums for a decade to find the best for every home and budget. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.

One of the best budget robot vacuums can take a lot of time and effort out of keeping your house clean, without taking a huge chunk out of your bank balance. While you can easily end up paying a ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

with the potential to completely upend white-collar jobs through language models and software agents – as well as blue-collar jobs through a rising generation of intelligent humanoid robots.

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...